Warren and Hawley Introduce Bipartisan Bill to Break Up Vertically Integrated Healthcare Giants

WASHINGTON — In a significant bipartisan move, Senators Elizabeth Warren (D-Mass.) and Josh Hawley (R-Mo.) introduced the Break Up Big Medicine Act on February 10, 2026, a piece of legislation aimed at dismantling the vertically integrated corporate structures that have come to dominate the U.S. healthcare industry. The bill proposes a direct prohibition on common ownership across different segments of the healthcare system. If enacted, it would become unlawful for a single entity to own or control both a healthcare provider or management services organization (MSO) and a health insurance company or pharmacy benefit manager (PBM). The legislation would also forbid common ownership of a provider or MSO and a prescription drug or medical device wholesaler. This legislative effort targets what its sponsors describe as rampant consolidation that drives up patient costs, stifles competition, and creates structural conflicts of interest. Proponents argue that when a single corporation owns the insurer, the PBM, and the clinics, it can steer patients to its own services, limit choices, and prioritize profits over care. According to a statement from Senator Warren's office, this trend has contributed to the closure of nearly 4,000 independent pharmacies since 2019 and resulted in almost 80 percent of physicians now being employed by a corporate parent. The proposed law would apply to both new and existing ownership structures. Companies found to be in violation would be given a one-year grace period to divest assets and bring their holdings into compliance. Enforcement authority would be granted to a wide range of bodies, including the Federal Trade Commission (FTC), the Department of Justice (DOJ), the Department of Health and Human Services, state attorneys general, and private parties, who would be empowered to bring legal action. The bill’s sponsors point to historical precedents for such structural separations in other industries, such as banking and railroads, where joint ownership was prohibited to protect consumers and ensure fair competition. The legislation seeks to restore PBMs, for example, to their original function as independent negotiators working to lower drug prices on behalf of insurers, rather than as integrated parts of insurance conglomerates that may benefit from higher prices. For small and mid-sized businesses, particularly independent medical practices and pharmacies, the act could represent a major shift in the competitive landscape. These smaller entities often struggle to compete with large, integrated systems that control vast networks and referral streams. By breaking up these conglomerates, the bill aims to level the playing field and create more opportunities for independent providers to operate. However, the legislation is not without its critics and potential complications. An analysis from the law firm Jones Day noted that ambiguities in the bill's text could lead to unintended consequences, potentially forcing divestitures at long-established integrated health systems that are not the primary conglomerates targeted by the bill. The broad language could inadvertently disrupt efficient and patient-friendly models of care that have developed over decades. The bipartisan nature of the bill is notable in a polarized Congress, suggesting that concerns over healthcare consolidation have cross-party appeal. This federal proposal also mirrors legislative efforts at the state level. For instance, Arkansas recently passed a law prohibiting PBMs from owning pharmacies, reflecting a similar structural-separation approach, although that law is currently facing a legal challenge. For healthcare investors and diversified medical platforms, the bill introduces significant regulatory risk. If it gains traction, it could force a fundamental restructuring of many of the largest players in the American healthcare market, such as UnitedHealth Group, which operates across insurance, PBM, and provider services segments. The potential for forced divestitures could reshape investment strategies and valuations across the sector. In our experience, legislation of this magnitude creates both immense challenges and unique opportunities for small and mid-sized businesses. While the Break Up Big Medicine Act is aimed at industry giants, its ripple effects will be felt by every practice and healthcare-related company. The prospect of forced divestitures could unlock a wave of assets, creating acquisition targets for smaller, strategic buyers or prompting new partnership models to emerge. Navigating this period of uncertainty requires sophisticated financial planning and a clear understanding of market dynamics. Business owners must be prepared to re-evaluate their strategic plans, from capital structure to growth strategy, in anticipation of a potentially fragmented and reconfigured industry. This is precisely the kind of complex environment where expert guidance on mergers and acquisitions becomes invaluable. For businesses considering how to position themselves for these changes, the team at C&S Finance Group LLC can provide the necessary strategic counsel at csfinancegroup.com. The bill's journey through the legislative process is just beginning and its passage is far from certain. However, its introduction alone signals a growing political appetite for aggressive structural reforms to address healthcare costs and competition. Business leaders, investors, and providers across the industry will be closely watching its progress, as its outcome could redefine the business of medicine in the United States for years to come.